Cargando…

Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains

Cystic fibrosis (CF) patients have chronic airway infection and frequent exposure to antibiotics, which often leads to the emergence of resistant organisms. Achromobacter xylosoxidans is a new emergent pathogen in CF spectrum. From 2005 to 2010 we had an outbreak in A. xylosoxidans prevalence in our...

Descripción completa

Detalles Bibliográficos
Autores principales: Trancassini, Maria, Iebba, Valerio, Citerà, Nicoletta, Tuccio, Vanessa, Magni, Annarita, Varesi, Paola, De Biase, Riccardo V., Totino, Valentina, Santangelo, Floriana, Gagliardi, Antonella, Schippa, Serena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982067/
https://www.ncbi.nlm.nih.gov/pubmed/24772108
http://dx.doi.org/10.3389/fmicb.2014.00138
_version_ 1782311135243927552
author Trancassini, Maria
Iebba, Valerio
Citerà, Nicoletta
Tuccio, Vanessa
Magni, Annarita
Varesi, Paola
De Biase, Riccardo V.
Totino, Valentina
Santangelo, Floriana
Gagliardi, Antonella
Schippa, Serena
author_facet Trancassini, Maria
Iebba, Valerio
Citerà, Nicoletta
Tuccio, Vanessa
Magni, Annarita
Varesi, Paola
De Biase, Riccardo V.
Totino, Valentina
Santangelo, Floriana
Gagliardi, Antonella
Schippa, Serena
author_sort Trancassini, Maria
collection PubMed
description Cystic fibrosis (CF) patients have chronic airway infection and frequent exposure to antibiotics, which often leads to the emergence of resistant organisms. Achromobacter xylosoxidans is a new emergent pathogen in CF spectrum. From 2005 to 2010 we had an outbreak in A. xylosoxidans prevalence in our CF center, thus, the present study was aimed at deeply investigating virulence traits of A. xylosoxidans strains isolated from infected CF patients. To this purpose, we assessed A. xylosoxidans genome variability by randomly amplified polymorphic DNA (RAPD), biofilm production, antibiotic resistances, and motility. All A. xylosoxidans strains resulted to be biofilm producers, and were resistant to antibiotics usually employed in CF treatment. Hodge Test showed the ability to produce carbapenemase in some strains. Strains who were resistant to β-lactamics antibiotics, showed the specific band related to metal β-lactamase (bla(IMP-1)), and some of them showed to possess the integron1. Around 81% of A. xylosoxidans strains were motile. Multivariate analysis showed that RAPD profiles were able to predict Forced Expiratory Volume (FEV1%) and biofilm classes. A significant prevalence of strong biofilm producers strains was found in CF patients with severely impaired lung functions (FEV1% class 1). The outbreak we had in our center (prevalence from 8.9 to 16%) could be explained by an enhanced adaptation of A. xylosoxidans in the nosocomial environment, despite of aggressive antibiotic regimens that CF patients usually undergo.
format Online
Article
Text
id pubmed-3982067
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-39820672014-04-25 Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains Trancassini, Maria Iebba, Valerio Citerà, Nicoletta Tuccio, Vanessa Magni, Annarita Varesi, Paola De Biase, Riccardo V. Totino, Valentina Santangelo, Floriana Gagliardi, Antonella Schippa, Serena Front Microbiol Public Health Cystic fibrosis (CF) patients have chronic airway infection and frequent exposure to antibiotics, which often leads to the emergence of resistant organisms. Achromobacter xylosoxidans is a new emergent pathogen in CF spectrum. From 2005 to 2010 we had an outbreak in A. xylosoxidans prevalence in our CF center, thus, the present study was aimed at deeply investigating virulence traits of A. xylosoxidans strains isolated from infected CF patients. To this purpose, we assessed A. xylosoxidans genome variability by randomly amplified polymorphic DNA (RAPD), biofilm production, antibiotic resistances, and motility. All A. xylosoxidans strains resulted to be biofilm producers, and were resistant to antibiotics usually employed in CF treatment. Hodge Test showed the ability to produce carbapenemase in some strains. Strains who were resistant to β-lactamics antibiotics, showed the specific band related to metal β-lactamase (bla(IMP-1)), and some of them showed to possess the integron1. Around 81% of A. xylosoxidans strains were motile. Multivariate analysis showed that RAPD profiles were able to predict Forced Expiratory Volume (FEV1%) and biofilm classes. A significant prevalence of strong biofilm producers strains was found in CF patients with severely impaired lung functions (FEV1% class 1). The outbreak we had in our center (prevalence from 8.9 to 16%) could be explained by an enhanced adaptation of A. xylosoxidans in the nosocomial environment, despite of aggressive antibiotic regimens that CF patients usually undergo. Frontiers Media S.A. 2014-04-03 /pmc/articles/PMC3982067/ /pubmed/24772108 http://dx.doi.org/10.3389/fmicb.2014.00138 Text en Copyright © 2014 Trancassini, Iebba, Citerà, Tuccio, Magni, Varesi, De Biase, Totino, Santangelo, Gagliardi and Schippa. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Trancassini, Maria
Iebba, Valerio
Citerà, Nicoletta
Tuccio, Vanessa
Magni, Annarita
Varesi, Paola
De Biase, Riccardo V.
Totino, Valentina
Santangelo, Floriana
Gagliardi, Antonella
Schippa, Serena
Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains
title Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains
title_full Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains
title_fullStr Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains
title_full_unstemmed Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains
title_short Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains
title_sort outbreak of achromobacter xylosoxidans in an italian cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982067/
https://www.ncbi.nlm.nih.gov/pubmed/24772108
http://dx.doi.org/10.3389/fmicb.2014.00138
work_keys_str_mv AT trancassinimaria outbreakofachromobacterxylosoxidansinanitaliancysticfibrosiscentergenomevariabilitybiofilmproductionantibioticresistanceandmotilityinisolatedstrains
AT iebbavalerio outbreakofachromobacterxylosoxidansinanitaliancysticfibrosiscentergenomevariabilitybiofilmproductionantibioticresistanceandmotilityinisolatedstrains
AT citeranicoletta outbreakofachromobacterxylosoxidansinanitaliancysticfibrosiscentergenomevariabilitybiofilmproductionantibioticresistanceandmotilityinisolatedstrains
AT tucciovanessa outbreakofachromobacterxylosoxidansinanitaliancysticfibrosiscentergenomevariabilitybiofilmproductionantibioticresistanceandmotilityinisolatedstrains
AT magniannarita outbreakofachromobacterxylosoxidansinanitaliancysticfibrosiscentergenomevariabilitybiofilmproductionantibioticresistanceandmotilityinisolatedstrains
AT varesipaola outbreakofachromobacterxylosoxidansinanitaliancysticfibrosiscentergenomevariabilitybiofilmproductionantibioticresistanceandmotilityinisolatedstrains
AT debiasericcardov outbreakofachromobacterxylosoxidansinanitaliancysticfibrosiscentergenomevariabilitybiofilmproductionantibioticresistanceandmotilityinisolatedstrains
AT totinovalentina outbreakofachromobacterxylosoxidansinanitaliancysticfibrosiscentergenomevariabilitybiofilmproductionantibioticresistanceandmotilityinisolatedstrains
AT santangelofloriana outbreakofachromobacterxylosoxidansinanitaliancysticfibrosiscentergenomevariabilitybiofilmproductionantibioticresistanceandmotilityinisolatedstrains
AT gagliardiantonella outbreakofachromobacterxylosoxidansinanitaliancysticfibrosiscentergenomevariabilitybiofilmproductionantibioticresistanceandmotilityinisolatedstrains
AT schippaserena outbreakofachromobacterxylosoxidansinanitaliancysticfibrosiscentergenomevariabilitybiofilmproductionantibioticresistanceandmotilityinisolatedstrains